DESMOPRESSIN ACETATE TRIHYDRATE ( DrugBank: Desmopressin, Acetate )


1 disease
IDDisease name (Link within this page)Number of trials
225Congenital nephrogenic diabetes insipidus1

225. Congenital nephrogenic diabetes insipidus


Clinical trials : 15 Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-001809-24-NL
(EUCTR)
31/07/201306/09/2012A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected?Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus)
MedDRA version: 15.0;Level: LLT;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications
MedDRA version: 15.0;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Code: SUB21605
INN or Proposed INN: desmopressin acetate trihydrate
Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands